Grifols, SA (ES:GRF)
BME:GRF
Want to see ES:GRF full AI Analyst Report?
Top Page
Grifols
(BME:GRF)
Select Model
Select Model
Rating:53Neutral
Price Target:
€9.00
▼(-0.55% Downside)
Action:ReiteratedDate:05/10/26
The score is driven primarily by improving profitability and positive free cash flow, partially offset by high leverage and soft recent revenue momentum. Technicals are weak (below major moving averages with negative MACD), while valuation is middle-of-the-road with only a modest dividend yield.
Positive Factors
Improved cash generation
Sustained positive operating cash flow (~€1.02B TTM) and solid free cash flow (~€0.75B TTM) provide durable capacity to fund operations, service debt and support reinvestment into manufacturing and plasma centers. This improves financial resilience across cycles.
Negative Factors
High leverage
Elevated leverage (debt/equity ~1.77 TTM) and rising total debt constrain strategic flexibility, increase interest exposure and amplify earnings volatility during revenue weakness. High leverage limits capacity to pursue large M&A or cushion prolonged downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved cash generation
Sustained positive operating cash flow (~€1.02B TTM) and solid free cash flow (~€0.75B TTM) provide durable capacity to fund operations, service debt and support reinvestment into manufacturing and plasma centers. This improves financial resilience across cycles.
Read all positive factors
Grifols (GRF) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€5.54B
Dividend Yield1.37%
Average Volume (3M)1.09M
Price to Earnings (P/E)18.7
Beta (1Y)0.97
Revenue Growth0.89%
EPS Growth112.68%
CountryES
Employees23,833
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.61
Shares Outstanding426,129,800
10 Day Avg. Volume1,216,950
30 Day Avg. Volume1,090,725
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.40
Price to Sales (P/S)0.98
P/FCF Ratio9.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.75Price Target Upside29.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.85
Revenue Forecast (FY)€7.73B
Grifols Business Overview & Revenue Model
Company Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience divi...
How the Company Makes Money
Grifols primarily makes money by collecting human plasma through its network of plasma donation centers and converting that plasma into plasma-derived medicines that are sold to hospitals, pharmacies, and healthcare systems. A key revenue stream c...
Grifols Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
48
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.44B | 7.52B | 7.21B | 6.59B | 6.06B | 4.93B |
| Gross Profit | 2.80B | 2.86B | 2.85B | 2.49B | 2.23B | 1.96B |
| EBITDA | 1.43B | 1.25B | 1.61B | 1.18B | 1.21B | 944.03M |
| Net Income | 415.17M | 401.89M | 156.92M | 59.31M | 208.28M | 265.33M |
Balance Sheet | ||||||
| Total Assets | 20.08B | 19.71B | 21.41B | 21.44B | 21.53B | 19.23B |
| Cash, Cash Equivalents and Short-Term Investments | 702.00M | 825.49M | 1.00B | 645.72M | 591.24M | 2.68B |
| Total Debt | 9.67B | 8.74B | 10.09B | 10.12B | 9.75B | 9.32B |
| Total Liabilities | 12.23B | 12.11B | 12.80B | 13.47B | 13.08B | 11.09B |
| Stockholders Equity | 5.46B | 5.27B | 5.88B | 5.83B | 6.13B | 6.10B |
Cash Flow | ||||||
| Free Cash Flow | 753.68M | 782.00M | 669.63M | -87.14M | -386.43M | 281.89M |
| Operating Cash Flow | 1.02B | 1.05B | 902.17M | 208.28M | -10.87M | 596.98M |
| Investing Cash Flow | -626.55M | -579.00M | 886.67M | -397.64M | -1.98B | -29.39M |
| Financing Cash Flow | -398.45M | -529.00M | -1.36B | 186.04M | -173.49M | 1.47B |
Grifols Technical Analysis
Neutral
9.05
Price Trends
9.90
Negative
10.38
Negative
11.12
Negative
Market Momentum
-0.09
Negative
56.04
Neutral
87.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:GRF, the sentiment is Neutral. The current price of 9.05 is below the 20-day moving average (MA) of 9.05, below the 50-day MA of 9.90, and below the 200-day MA of 11.12, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 56.04 is Neutral, neither overbought nor oversold. The STOCH value of 87.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:GRF.
Grifols Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €1.77B | 245.30 | 35.36% | 1.04% | 28.27% | 307.67% | |
61 Neutral | €3.18B | 108.93 | 20.89% | 1.50% | -3.44% | -5.45% | |
59 Neutral | €2.57B | 35.12 | 3.96% | 1.22% | 12.41% | 342.01% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €5.54B | 18.75 | 7.56% | 1.37% | 0.89% | 112.68% | |
51 Neutral | €1.50B | 14.71 | 18.13% | 3.51% | 23.66% | -28.51% | |
46 Neutral | €227.05M | 16.80 | 2.03% | 1.91% | -2.30% | -52.51% |
* General Sector Average
ES:GRF
Grifols
8.94
0.63
7.54%
ES:ALM
Almirall
11.96
1.32
12.43%
ES:FAE
Faes Farma
4.82
0.69
16.61%
ES:RJF
LABORATORIO REIG JOFRE
2.78
-0.20
-6.71%
ES:ROVI
Laboratorios Farmaceuticos Rovi
62.85
9.59
17.99%
ES:PHM
Pharma Mar SA
99.50
24.79
33.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.